Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

Punwani, Naresh; Burn, Timothy C.; Scherle, Peggy; Flores, Robert; Shi, Jack G.; Collier, Paul; Hertel, Denise; Haley, Patrick J.; Lo, Yvonne; Waeltz, Paul; Rodgers, James D.; Shepard, Stacey; Vaddi, Kris; Yeleswaram, Swamy; Levy, Richard S.; Williams, William V.; Gottlieb, Alice B.

doi:10.1111/bjd.13994

Cited by 60 publications

(43 citation statements)

References 16 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most improvement was observed in the 1.5% cream b.i.d. group, with mean baseline scores decreasing 60% after 28 days of treatment . Adverse effects were rare and limited to application site irritation reported in 20% of study participants .…”

Section: Efficacy Of Small Molecule Medicationsmentioning

confidence: 89%

Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

Turbeville

Patel

Cardwell

et al. 2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

New treatments continue to be developed for psoriasis. In this review, we aim to summarize the results of the major published studies on biologic and small molecule drugs for the treatment of psoriasis. We emphasize the safety, efficacy, and tolerability of these treatment options. A review of the MEDLINE database was conducted for each class of medication. Randomized controlled trials were identified for each medication; data on efficacy, safety, and tolerability were reviewed. Biologic and small molecule treatment options are more effective than placebo, although there were few head-to-head trials to assess relative efficacy between biologics and small molecule treatments. These drugs offer favorable safety profiles with only rare serious adverse events reported. Biologic and small molecule drugs offer diverse therapeutic regimens, particularly in patients with recalcitrant disease.

show abstract

Section: Efficacy Of Small Molecule Medicationsmentioning

confidence: 89%

Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

Turbeville

Patel

Cardwell

et al. 2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…This may indicate that systemic inflammation takes a longer time to cease than skin lesions or that signalling through the investigated pathways is maintained, at least in blood, by cytokines besides TNF‐α. Basal levels of pSTAT3 (Y705) in patients with psoriasis have been reported to be similar to those observed in healthy volunteers . The discrepancy between these findings and ours may be explained by different methodological approaches (enzyme‐linked immunosorbent assay was used in the study by Punwani et al …”

Section: Discussionmentioning

confidence: 56%

“…Basal levels of pSTAT3 (Y705) in patients with psoriasis have been reported to be similar to those observed in healthy volunteers . The discrepancy between these findings and ours may be explained by different methodological approaches (enzyme‐linked immunosorbent assay was used in the study by Punwani et al …”

Section: Discussionmentioning

confidence: 56%

Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Ruxolitinib (INCB018424) 1.0% and 1.5% creams applied twice daily led to reduction in psoriasis lesion size over 4 weeks 35 . Improvement in psoriasis was also observed with tofacitinib 2% ointment; however, the degree of improvement relative to controls was modest and not always statistically significant 36,37 .…”

Section: Psoriasismentioning

confidence: 99%

JAK inhibitors in dermatology: The promise of a new drug class

Damsky

King

2017

Journal of the American Academy of Dermatology

386

286

View full text Add to dashboard Cite

New molecularly targeted therapeutics are changing dermatologic therapy. JAK-STAT is an intracellular signaling pathway upon which many different pro-inflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors may be a useful therapeutic strategy for these diseases. There is growing evidence that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition may be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.

show abstract

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

Abstract: Topical INCB018424 dosed for 28 days QD or BID is pharmacologically active in patients with active psoriasis and modulates proinflammatory cytokines in the pathogenesis of psoriatic lesions.

Cited by 60 publications

References 16 publications

Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab

JAK inhibitors in dermatology: The promise of a new drug class

Contact Info

Product

Resources

About